Cardiac manifestations in primary antiphospholipid syndrome and their association to antiphospholipid antibodies' types and titers-cross-sectional study of Serbian cohort.
Aleksandra DjokovicLjudmila StojanovichNatasa StanisavljevicSandra DjokicBranka FilipovicPredrag MaticMilomir MilanovicSvetlana ApostolovicJovica SaponjskiPublished in: Clinical rheumatology (2022)
Certain cardiac manifestations in PAPS were related to certain aPL type and/or titer levels, imposing confirmation in prospective studies. Preventive actions, comprehending proper anticoagulant/antithrombotic therapy, and intense action against standard atherosclerotic risk factors are of utmost importance in this group of patients. Key Points • In Serbian patients with primary antiphospholipid syndrome (PAPS), prevalence of non-criteria cardiac manifestations was 19.6% and they were significantly related to certain antiphospholipid antibodies and titers. • Lupus anticoagulant was a meaningful predictor of myocardial infarction, enabling possible risk stratification and proper preventive and therapeutical strategies in this subgroup of PAPS patients. • Patients with high titers of aCL IgG are more prone to acute decompensated heart failure occurence, imposing careful follow-up of these patients • Based on the analysis of the Serbian PAPS cohort, even being non-criterial, cardiology manifestations are significantly present and inclusion of cardiologists in treatment and follow-up of these patients should be implied from the diagnosis establishment.
Keyphrases
- end stage renal disease
- heart failure
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- left ventricular
- clinical trial
- stem cells
- randomized controlled trial
- bone marrow
- venous thromboembolism
- cardiac surgery
- hepatitis b virus
- patient reported
- drug induced
- acute respiratory distress syndrome
- study protocol